Combining a programmed cell death protein-1 (PD-1) inhibitor (pembrolizumab [PEM]) with a second-generation androgen receptor (AR) antagonist (enzalutamide [ENZ]) at the time of comprehensive therapy for mCRPC has emerged as an option to potentially prolong the progression of cancer and improve OS [7]. The gene discussed is PDCD1; the disease is cancer.